Entera Bio to Report Interim Data From EB613 Phase 2 Trial and First Quarter 2020 Business and Financial Results on May 21, 2020
BOSTON and JERUSALEM, May 07, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report interim three-month top-line biomarker data for the first 50% of …